George Wilding, MD Print Friendly PageFaculty, University of Wisconsin School of Medicine and Public Health
George Wilding, MD was named Director of the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center in January 2004. A nationally renowned prostate cancer researcher, Wilding is the Donald and Marilyn Anderson professor of medicine and serves as head of the Medical Oncology section within the Department of Medicine at UW Medical School. He has been a UW Carbone Cancer Center member since joining the UW faculty in 1988.
A native of Everett, Massachusetts, Wilding graduated from the University of Massachusetts Medical School, where he also completed his internship and residency in Internal Medicine. He underwent training in Medical Oncology within the Medicine Branch at the National Cancer Institute. He has a master's degree (pharmacology) from Pennsylvania State University and bachelor's degrees from Tufts University (chemical engineering and biology).
UW Health Clinics
|Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.|
UW School of Medicine and Public Health
|Department of Medicine|
Professional Certifications and Education
National Cancer Institute, NIH, Bethesda, MD
University of Massachusetts Medical School, Worcester
University of Massachusetts Medical School, Worcester
University of Massachusetts Medical School, Worcester, MA, 1980
In his clinical practice, Wilding sees patients with genitourinary cancers, including prostate, kidney, testicular and bladder cancers. From 1995 to 2003, he directed the UW Carbone Cancer Center Experimental Therapeutics Program, which seeks to identify new anti-cancer agents in the laboratory and translate them into clinical treatments with human patients. He served as chairman of the Genitourinary Cancer Committee of the Eastern Cooperative Oncology Group, a National Cancer Institute (NCI)-sponsored clinical research group for 10 years until 2003, and serves on numerous NCI, industry and foundation advisory and review boards.
Cetnar J Wilding G McNeel D Loconte NK McFarland TA Eickhoff J Liu G .
A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer. Urol Oncol. 2013 May;31(4):436-41
[PubMed ID: 21481618]
Liu G Chen YH Kolesar J Huang W Dipaola R Pins M Carducci M Stein M Bubley GJ Wilding G .
Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer. Urol Oncol. 2013 Feb;31(2):211-8
[PubMed ID: 21784672]
Gee J Bailey H Kim K Kolesar J Havighurst T Tutsch KD See W Cohen MB Street N Levan L Jarrard D Wilding G .
Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin. Prostate. 2013 Jan 17;
[PubMed ID: 23335089]
McNeel DG Smith HA Eickhoff JC Lang JM Staab MJ Wilding G Liu G .
Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunol Immunother. 2012 Jul;61(7):1137-47
[PubMed ID: 22210552]
Liu G Chen YH Dipaola R Carducci M Wilding G .
Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group. Clin Genitourin Cancer. 2012 Jun;10(2):99-105
[PubMed ID: 22386239]
Holen K DiPaola R Liu G Tan AR Wilding G Hsu K Agrawal N Chen C Xue L Rosenberg E Stein M .
A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors. Invest New Drugs. 2012 Jun;30(3):1088-95
[PubMed ID: 21424701]
Tevaarwerk A Wilding G Eickhoff J Chappell R Sidor C Arnott J Bailey H Schelman W Liu G .
Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design. Invest New Drugs. 2012 Jun;30(3):1039-45
[PubMed ID: 21225315]
Bruce JY Eickhoff J Pili R Logan T Carducci M Arnott J Treston A Wilding G Liu G .
A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate. Invest New Drugs. 2012 Apr;30(2):794-802
[PubMed ID: 21174224]
Liu G Jeraj R Vanderhoek M Perlman S Kolesar J Harrison M Simoncic U Eickhoff J Carmichael L Chao B Marnocha R Ivy P Wilding G .
Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate. Clin Cancer Res. 2011 Dec 15;17(24):7634-44
[PubMed ID: 22038997]
Harrison MR Hahn NM Pili R Oh WK Hammers H Sweeney C Kim K Perlman S Arnott J Sidor C Wilding G Liu G .
A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Invest New Drugs. 2011 Dec;29(6):1465-74
[PubMed ID: 20499131]
Lang JM Kaikobad MR Wallace M Staab MJ Horvath DL Wilding G Liu G Eickhoff JC McNeel DG Malkovsky M .
Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma. Cancer Immunol Immunother. 2011 Oct;60(10):1447-60
[PubMed ID: 21647691]
Traynor AM Thomas JP Ramanathan RK Mody TD Alberti D Wilding G Bailey HH .
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies. Invest New Drugs. 2011 Apr;29(2):316-22
[PubMed ID: 19997959]
Basu HS Mahlum A Mehraein-Ghomi F Kegel SJ Guo S Peters NR Wilding G .
Pretreatment with anti-oxidants sensitizes oxidatively stressed human cancer cells to growth inhibitory effect of suberoylanilide hydroxamic acid (SAHA). Cancer Chemother Pharmacol. 2011 Mar;67(3):705-15
[PubMed ID: 20512578]
Holen KD Belani CP Wilding G Ramalingam S Volkman JL Ramanathan RK Vasist LS Bowen CJ Hodge JP Dar MM Ho PT .
A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose. Cancer Chemother Pharmacol. 2011 Feb;67(2):447-54
[PubMed ID: 20461380]
Kolesar J Brundage RC Pomplun M Alberti D Holen K Traynor A Ivy P Wilding G .
Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients. Cancer Chemother Pharmacol. 2011 Feb;67(2):393-400
[PubMed ID: 20440618]
Traynor AM Hewitt M Liu G Flaherty KT Clark J Freedman SJ Scott BB Leighton AM Watson PA Zhao B O'Dwyer PJ Wilding G .
Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011 Feb;67(2):305-14
[PubMed ID: 20386909]
Schelman WR Liu G Wilding G Morris T Phung D Dreicer R .
A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer. Invest New Drugs. 2011 Feb;29(1):118-25
[PubMed ID: 19763400]
Kolesar JM Sachidanandam K Schelman WR Eickhoff J Holen KD Traynor AM Alberti DB Thomas JP Chitambar CR Wilding G Antholine WE .
Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electron Paramagnetic Resonance. Exp Ther Med. 2011 Jan;2(1):119-123
[PubMed ID: 21373381]
Ewald JA Desotelle JA Wilding G Jarrard DF .
Therapy-induced senescence in cancer. J Natl Cancer Inst. 2010 Oct 20;102(20):1536-46
[PubMed ID: 20858887]
Choi BS Alberti DB Schelman WR Kolesar JM Thomas JP Marnocha R Eickhoff JC Ivy SP Wilding G Holen KD .
The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors. Cancer Chemother Pharmacol. 2010 Oct;66(5):973-80
[PubMed ID: 20127092]
Traynor AM Gordon MS Alberti D Mendelson DS Munsey MS Wilding G Gammans RE Read WL .
A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors. Invest New Drugs. 2010 Aug;28(4):509-15
[PubMed ID: 19434370]